Why the FDA is making a test case of a cancer drug from China
At a quick glance, the Food and Drug Administration's decision to ask its advisers for help in vetting yet another cancer immunotherapy may seem odd.
After all, the ...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement